Ignite Creation Date:
2024-05-06 @ 1:41 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01878396
Status:
UNKNOWN
Last Update Posted:
2016-10-03
First Post:
2013-06-07
Brief Title:
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
Sponsor:
Istituto Oncologico Veneto IRCCS
Organization:
Istituto Oncologico Veneto IRCCS
Study Overview
Official Title:
Predictive Value of Circulating Melanoma Cells CMCs in Metastatic Melanoma MM Patients Treated With Selective Inhibitors of BRAF
Status:
UNKNOWN
Status Verified Date:
2016-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CMCBRAF
Brief Summary:
The purpose of this study is to evaluate Circulating Melanoma Cell CMC changes in Metastatic Melanoma MM patients undergoing treatment with selective inhibitors of mutated BRAF
Detailed Description:
This is an observational prospective pilot study aimed to investigate the association between changes of total and apoptotic CMC count and disease progression in MM patients undergoing treatment with selective inhibitors of mutated B-RAF
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CE IOV 201135 | OTHER | Comitato Etico IOV | None |